Concepts (116)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Staphylococcal Skin Infections | 1 | 2020 | 1 | 0.670 |
Why?
|
| Meningitis, Cryptococcal | 2 | 2018 | 4 | 0.670 |
Why?
|
| Staphylococcus aureus | 1 | 2020 | 11 | 0.670 |
Why?
|
| Soft Tissue Infections | 1 | 2020 | 7 | 0.670 |
Why?
|
| Fosfomycin | 1 | 2020 | 1 | 0.650 |
Why?
|
| Pyelonephritis | 1 | 2020 | 3 | 0.650 |
Why?
|
| Urinary Tract Infections | 1 | 2020 | 9 | 0.650 |
Why?
|
| Humans | 18 | 2025 | 6794 | 0.540 |
Why?
|
| Cryptococcus neoformans | 1 | 2017 | 2 | 0.530 |
Why?
|
| Skin Ulcer | 1 | 2017 | 3 | 0.530 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 7 | 0.530 |
Why?
|
| Antibodies, Viral | 3 | 2025 | 14 | 0.510 |
Why?
|
| Male | 11 | 2025 | 3671 | 0.460 |
Why?
|
| HIV Infections | 3 | 2025 | 432 | 0.440 |
Why?
|
| Vaccination | 2 | 2025 | 49 | 0.410 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2012 | 1 | 0.370 |
Why?
|
| Hydrocephalus | 1 | 2012 | 2 | 0.370 |
Why?
|
| Adult | 9 | 2025 | 2113 | 0.370 |
Why?
|
| Antibodies, Neutralizing | 3 | 2025 | 9 | 0.340 |
Why?
|
| Meningomyelocele | 1 | 2010 | 1 | 0.330 |
Why?
|
| Scoliosis | 1 | 2010 | 1 | 0.330 |
Why?
|
| Spinal Fusion | 1 | 2010 | 2 | 0.320 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 73 | 0.320 |
Why?
|
| Postoperative Complications | 1 | 2010 | 109 | 0.310 |
Why?
|
| Biomarkers | 3 | 2025 | 214 | 0.290 |
Why?
|
| Retrospective Studies | 3 | 2020 | 681 | 0.280 |
Why?
|
| Antibodies, Monoclonal | 2 | 2025 | 31 | 0.280 |
Why?
|
| Fluconazole | 2 | 2018 | 3 | 0.270 |
Why?
|
| Antifungal Agents | 2 | 2018 | 9 | 0.270 |
Why?
|
| Middle Aged | 7 | 2025 | 2108 | 0.260 |
Why?
|
| Female | 8 | 2025 | 4060 | 0.250 |
Why?
|
| Hospitalization | 2 | 2025 | 128 | 0.250 |
Why?
|
| Quinolines | 1 | 2025 | 2 | 0.230 |
Why?
|
| Point-of-Care Testing | 1 | 2025 | 2 | 0.230 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2025 | 24 | 0.230 |
Why?
|
| Hepatitis B | 1 | 2025 | 9 | 0.220 |
Why?
|
| Hepatitis B Vaccines | 1 | 2025 | 8 | 0.220 |
Why?
|
| Adjuvants, Immunologic | 1 | 2025 | 9 | 0.220 |
Why?
|
| Point-of-Care Systems | 1 | 2025 | 8 | 0.220 |
Why?
|
| Risk Factors | 2 | 2020 | 767 | 0.210 |
Why?
|
| Prospective Studies | 2 | 2024 | 331 | 0.200 |
Why?
|
| Aged | 5 | 2025 | 1539 | 0.190 |
Why?
|
| Respiratory Insufficiency | 1 | 2023 | 9 | 0.190 |
Why?
|
| Impetigo | 1 | 2020 | 1 | 0.170 |
Why?
|
| Methicillin Resistance | 1 | 2020 | 1 | 0.170 |
Why?
|
| Abscess | 1 | 2020 | 2 | 0.170 |
Why?
|
| Cellulitis | 1 | 2020 | 2 | 0.170 |
Why?
|
| Drainage | 1 | 2020 | 10 | 0.170 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2020 | 14 | 0.170 |
Why?
|
| Habits | 1 | 2020 | 1 | 0.160 |
Why?
|
| Escherichia coli | 1 | 2020 | 8 | 0.160 |
Why?
|
| Algorithms | 1 | 2020 | 83 | 0.160 |
Why?
|
| Anti-HIV Agents | 1 | 2021 | 102 | 0.160 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 71 | 0.160 |
Why?
|
| Child | 2 | 2012 | 524 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2024 | 82 | 0.150 |
Why?
|
| Case-Control Studies | 2 | 2025 | 108 | 0.150 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2018 | 49 | 0.140 |
Why?
|
| Flucytosine | 1 | 2017 | 1 | 0.130 |
Why?
|
| Amphotericin B | 1 | 2017 | 4 | 0.130 |
Why?
|
| Thigh | 1 | 2017 | 4 | 0.130 |
Why?
|
| Necrosis | 1 | 2017 | 30 | 0.130 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 79 | 0.130 |
Why?
|
| Treatment Outcome | 3 | 2024 | 500 | 0.130 |
Why?
|
| Adolescent | 2 | 2023 | 869 | 0.120 |
Why?
|
| Multicenter Studies as Topic | 2 | 2024 | 15 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2024 | 26 | 0.100 |
Why?
|
| Double-Blind Method | 2 | 2023 | 101 | 0.090 |
Why?
|
| Survival | 1 | 2012 | 1 | 0.090 |
Why?
|
| Equipment Failure | 1 | 2012 | 6 | 0.090 |
Why?
|
| Prosthesis Implantation | 1 | 2012 | 15 | 0.090 |
Why?
|
| Equipment Design | 1 | 2012 | 20 | 0.090 |
Why?
|
| Reoperation | 1 | 2012 | 17 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 42 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 140 | 0.090 |
Why?
|
| Infant | 1 | 2012 | 187 | 0.090 |
Why?
|
| Infant, Newborn | 1 | 2012 | 199 | 0.090 |
Why?
|
| Age Factors | 1 | 2012 | 193 | 0.090 |
Why?
|
| Child, Preschool | 1 | 2012 | 258 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 268 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2012 | 285 | 0.080 |
Why?
|
| Preoperative Period | 1 | 2010 | 6 | 0.080 |
Why?
|
| Bacterial Infections | 1 | 2010 | 12 | 0.080 |
Why?
|
| Malnutrition | 1 | 2010 | 51 | 0.080 |
Why?
|
| Nutritional Status | 1 | 2010 | 64 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2010 | 197 | 0.080 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2025 | 3 | 0.060 |
Why?
|
| Placebos | 1 | 2025 | 10 | 0.060 |
Why?
|
| Aluminum Hydroxide | 1 | 2025 | 1 | 0.060 |
Why?
|
| Dinucleoside Phosphates | 1 | 2025 | 1 | 0.060 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2025 | 3 | 0.060 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2025 | 4 | 0.060 |
Why?
|
| Hepatitis B Antibodies | 1 | 2025 | 4 | 0.060 |
Why?
|
| Injections, Intramuscular | 1 | 2025 | 6 | 0.060 |
Why?
|
| Immunization Schedule | 1 | 2025 | 7 | 0.060 |
Why?
|
| Feasibility Studies | 1 | 2025 | 44 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2025 | 98 | 0.060 |
Why?
|
| Adaptive Clinical Trials as Topic | 1 | 2024 | 1 | 0.050 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2024 | 1 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2024 | 45 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2024 | 36 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2024 | 20 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2024 | 19 | 0.050 |
Why?
|
| Demography | 1 | 2023 | 26 | 0.050 |
Why?
|
| Pandemics | 1 | 2024 | 87 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2023 | 5 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2022 | 10 | 0.050 |
Why?
|
| Inpatients | 1 | 2022 | 22 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2023 | 497 | 0.040 |
Why?
|
| Public Sector | 1 | 2021 | 2 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 20 | 0.040 |
Why?
|
| Young Adult | 1 | 2023 | 567 | 0.040 |
Why?
|
| Viral Load | 1 | 2021 | 26 | 0.040 |
Why?
|
| South Africa | 1 | 2021 | 68 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2021 | 31 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2018 | 23 | 0.030 |
Why?
|